AR064379A1 - COMPOUNDS WITH A CANNABINOID CB1 ANTAGONISM COMBINATION AND ACETILCOLINESTERASE INHIBITION - Google Patents

COMPOUNDS WITH A CANNABINOID CB1 ANTAGONISM COMBINATION AND ACETILCOLINESTERASE INHIBITION

Info

Publication number
AR064379A1
AR064379A1 ARP070105654A AR064379A1 AR 064379 A1 AR064379 A1 AR 064379A1 AR P070105654 A ARP070105654 A AR P070105654A AR 064379 A1 AR064379 A1 AR 064379A1
Authority
AR
Argentina
Prior art keywords
compounds
cannabinoid
methods
preparing
refers
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Josephus H M Lange
Cornelis G Kruse
Belal Shadid
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of AR064379A1 publication Critical patent/AR064379A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se refiere a compuestos con una combinacion de antagonismo de CB1 cannabinoide e inhibicion de colinesterasa, a composiciones farmacéuticas que contienen estos compuestos, a métodos para preparar estos compuestos, métodos para preparar novedosos intermediarios utiles para su síntesis, y métodos para preparar composiciones. También se refiere a los usos de tales compuestos y composiciones, particularmente para tratar la enfermedad de Alzheimer, trastornos cognitivos, trastornos de la memoria, demencia, deficiencias de atencion, dano cerebral traumático, dependencia de drogas, adiccion y abuso de sustancias. Reivindicacion 3: Un compuesto segun lo reivindicado en la reivindicacion 1, que tiene la formula (1) o un tautomero, estereoisomero, N-oxido, análogo isotopicamente marcado o una sal, hidrato o solvato farmacologicamente aceptable de cualquiera de los anteriores, en donde: A representa un elemento estructural esencial de cualquier antagonista de CB1 cannabinoide conocido que contiene al menos dos anillos fenilo, independientemente opcionalmente sustituidos con uno o dos sustituyentes seleccionados del grupo que consiste de halogeno, metoxi y trifluorometilo, estando dicho elemento estructural esencial unido a un aceptor de enlace hidrogeno en dicho antagonista de CB1. Reivindicacion 11: Un compuesto segun lo reivindicado en la reivindicacion 3 de la formula (1) seleccionado de las formulas (2) y (3).It refers to compounds with a combination of cannabinoid CB1 antagonism and cholinesterase inhibition, pharmaceutical compositions containing these compounds, methods for preparing these compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. It also refers to the uses of such compounds and compositions, particularly to treat Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficiencies, traumatic brain damage, drug dependence, addiction and substance abuse. Claim 3: A compound as claimed in claim 1, having the formula (1) or a tautomer, stereoisomer, N-oxide, isotopically labeled analogue or a pharmacologically acceptable salt, hydrate or solvate of any of the foregoing, wherein : A represents an essential structural element of any known cannabinoid CB1 antagonist containing at least two phenyl rings, independently optionally substituted with one or two substituents selected from the group consisting of halogen, methoxy and trifluoromethyl, said essential structural element being attached to a hydrogen bond acceptor in said CB1 antagonist. Claim 11: A compound as claimed in claim 3 of the formula (1) selected from formulas (2) and (3).

ARP070105654 2006-12-20 2007-12-17 COMPOUNDS WITH A CANNABINOID CB1 ANTAGONISM COMBINATION AND ACETILCOLINESTERASE INHIBITION AR064379A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06126584 2006-12-20

Publications (1)

Publication Number Publication Date
AR064379A1 true AR064379A1 (en) 2009-04-01

Family

ID=38024247

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105654 AR064379A1 (en) 2006-12-20 2007-12-17 COMPOUNDS WITH A CANNABINOID CB1 ANTAGONISM COMBINATION AND ACETILCOLINESTERASE INHIBITION

Country Status (7)

Country Link
CN (1) CN101848907A (en)
AR (1) AR064379A1 (en)
BR (1) BRPI0721060A2 (en)
IN (1) IN2009CN03566A (en)
MX (1) MX2009006889A (en)
TW (1) TW200843772A (en)
ZA (1) ZA200903779B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4183264A1 (en) * 2020-07-14 2023-05-24 Liscure Biosciences Co., Ltd. Composition for treating brain disease comprising pediococcus inopinatus or extracellular vesicles derived therefrom as active ingredient
WO2022089598A1 (en) * 2020-10-30 2022-05-05 杭州拉林智能科技有限公司 Flavonoid glycoside-organic amine neuroagonist double salt compound, preparation method therefor, and application thereof

Also Published As

Publication number Publication date
TW200843772A (en) 2008-11-16
CN101848907A (en) 2010-09-29
MX2009006889A (en) 2009-07-07
BRPI0721060A2 (en) 2014-02-25
ZA200903779B (en) 2010-04-28
IN2009CN03566A (en) 2015-08-07

Similar Documents

Publication Publication Date Title
AR121661A2 (en) NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF
AR049276A1 (en) OPIOOD CARBOXAMID COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR059064A1 (en) TIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES IN THE TREATMENT OF DISEASES MEDIATED BY PROTEIN KINASE B (PKB), SUCH AS CANCER.
EA201290260A1 (en) BENZIMIDAZOL-IMIDAZOL DERIVATIVES
AR067662A1 (en) BENZO DERIVATIVES [D] ISOXAZOL-3-IL-PIPERIDINE, MEDICINES CONTAINING THERAPEUTIC USES AND DISEASES FOR DISEASES ASSOCIATED WITH THE NERVOUS SYSTEM.
AR061369A1 (en) PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
BRPI0415657A (en) dihydrobenzofuranyl alkanamine derivatives as 5ht2c agonists
AR061371A1 (en) AMINO - IMIDAZOLONAS AND ITS USE AS A MEDICINAL PRODUCT FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES.
AR094346A1 (en) DERIVATIVES OF AZAINDOL AS INHIBITORS OF PROTEIN KINASES
AR051026A1 (en) HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
AR096979A1 (en) DERIVATIVES OF PIRROL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR107633A1 (en) PROCEDURE FOR THE PREPARATION OF ACID 4-PHENYL-5-ALCOXICARBONIL-2-TIAZOL-2-IL-1,4-DIHYDROPIRIMIDIN-6-IL- [METHYL] -3-OXO-5,6,8,8A-TETRAHIDRO- 1H-IMIDAZO [1,5A] PIRAZIN-2-IL-CARBOXYL
EA201001683A1 (en) Derivatives of phenyl or pyridinyl substituted indazols
RS53341B (en) Cis-tetrahydro-spiro(cyclohexan-1,1'-pyrido[3,4-b]indol)-4-amine derivatives
AR062907A1 (en) DERIVATIVES OF SULFONILPIRAZOL AND SULFONILPIRAZOLINCARBOXAMIDINE AS ANTAGONISTS OF 5-HT6
AR047531A1 (en) DERIVATIVES 1H-TIENO (2,3-C) PIRAZOL USEFUL AS QUINASE INHIBITORS
WO2009065922A3 (en) Organic compounds
AR105522A1 (en) DERIVATIVES OF REPLACED AMIDA THAT HAVE MULTIMODAL ACTIVITY AGAINST PAIN
EA201071269A1 (en) 3,4-REPLACED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
EA200970596A1 (en) COMPOUNDS WITH THE COMBINATION OF ANTAGONISTIC ACTIVITY WITH RESPECT TO CANANABINOID RECEPTORS OF SVI INHIBITIVE ACTIVITY WITH RESPECT TO ACETYL CHOLINESTERASE
AR068111A1 (en) COMPOSITE PIRAZINA AND PIPERIDIN REPLACED PIPERAZINIL, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT
NO20075477L (en) Tetrahydro-pyridoazepin-8-one and related compounds for the treatment of schizophrenia
DK1893589T3 (en) Substituted N-benzo [d] isoxazol-3-yl-amine derivatives as inhibitors of mGluR5, serotonin (5-HT) and norepinephrine receptors and their use in the preparation of drugs
AR067873A1 (en) BENZOIL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS
AR064379A1 (en) COMPOUNDS WITH A CANNABINOID CB1 ANTAGONISM COMBINATION AND ACETILCOLINESTERASE INHIBITION

Legal Events

Date Code Title Description
FA Abandonment or withdrawal